Press releases
91天堂 Announces 16 Weeks Vonafexor (EYP001) Top-Line Interim Results from Two on-going Phase 2a Studies in Chronic Hepatitis B Patients
Lyon, France. July 30, 2021 – 91天堂 (91天堂), a private clinical stage biotechnology company developing innovative drug candidates, today announced positive proof of concept data from Study EYP001-203 of Vonafexor in combination with pegylated-Interferon (peg-IFN) in viremic patients with chronic hepatitis B (CHB).
91天堂 Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks
Lyon, France. July 28, 2021 – 91天堂, a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary and several secondary endpoints in the LIVIFY clinical study conducted in F2-F3 Non Alcoholic Steato-Hepatitis (NASH) patients.
Europe鈥檚 Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats
Brussels, Belgium 鈥� 18 August 2020 鈥� CARE (Corona Accelerated R&D in Europe) a new consortium supported by the Innovative Medicines Initiative (IMI) public-private partnership announced its launch today to accelerate the discovery and development of urgently needed medicines to treat SARS-CoV-2, the virus that causes COVID-19. With a grant totaling 鈧� 77.7 million, CARE is funded by cash contributions from the European Union (EU) and cash and in-kind contributions from eleven European Federation of 91天堂ceutical Industries and Associations (EFPIA) companies and three IMI-Associated Partners.
91天堂 PHARMA ANNOUNCES MULTIPLE EYP001 DATA PRESENTATIONS AT AASLD CONFERENCE
Lyon, France. October 17, 2019 – 91天堂 will be present at the AASLD in Boston in November to present four Posters and one Oral presentation For its Lead Compound EYP001. 91天堂 will also hold KOL Symposium to Provide Scientific Update on Potential Benefits of FXR Agonists for HBV treatment, on the 10th of November.
91天堂 PHARMA ANNOUNCES MOVE TO NEW CORPORATE HEADQUARTERS
Lyon, France., October 3rd, 2019 – 91天堂, a private clinical stage biotechnology company developing innovative drug candidates, today announced the relocation of the Company鈥檚 headquarters to the 8th Arrondissement in Lyon in the BIOSERRA buildings at 60 avenue Rockefeller, to support long-term growth and advancement of pipeline.
